Antibiotic resistance in patients with liver cirrhosis:Prevalence and current approach to tackle  

作　　者：Valentina Liakina 

机构地区：[1]Clinic of Gastroenterology,Nephrourology and Surgery,Institute of Clinical Medicine,Faculty of Medicine,Vilnius University,Vilnius 01513,Lithuania [2]Department of Chemistry and Bioengineering,Faculty of Fundamental Sciences,Vilnius Tech,Vilnius 10223,Lithuania

出　　处：《World Journal of Clinical Cases》2023年第31期7530-7542,共13页世界临床病例杂志

摘　　要：Regardless of etiology,complications with bacterial infection in patients with cirrhosis are reported in the range of 25%-46%according to the most recent data.Due to frequent episodes of bacterial infection and repetitive antibiotic treatment,most often with broad-spectrum gram negative coverage,patients with cirrhosis are at increased risk of encountering multidrug resistant bacteria,and this raises concern.In such patients,extended-spectrum beta-lactamase and AmpCproducing Enterobacterales,methicillin-or vancomycin-resistant Staphylococcus aureus,vancomycin-resistant Enterococci,carbapenem-resistant Pseudomonas aeruginosa,and Acinetobacter baumannii,all of which are difficult to treat,are the most common.That is why novel approaches to the prophylaxis and treatment of bacterial infections to avoid antibiotic resistance have recently been developed.At the same time,our knowledge of resistance mechanisms is constantly updated.This review summarizes the current situation regarding the burden of antibiotic resistance,including the prevalence and mechanisms of intrinsic and acquired resistance in bacterial species that most frequently cause complications in patients with liver cirrhosis and recent developments on how to deal with multidrug resistant bacteria.

关 键 词：CIRRHOSIS Bacterial complications ANTIBIOTICS Intrinsic resistance Acquired resistance PROBIOTICS Vaccines 

分 类 号：R575.2[医药卫生—消化系统]